Skip to main content
Download PDF

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation

Human Genomics volume 17, Article number: 59 (2023) Cite this article

Abstract

Background

The influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood. This study aimed to explore the effects of CYP3A4/5, ABCB1, and ABCG2 gene polymorphisms on the trough concentrations and the bleeding risk of rivaroxaban in NVAF patients.

Patients and methods

This study is a prospective multicenter study. The patient's blood samples were collected to detect the steady-state trough concentrations of rivaroxaban and gene polymorphisms. We visited the patients regularly at month 1, 3, 6, and 12 to record bleeding events and medications.

Results

A total of 95 patients were enrolled in this study, and 9 gene loci were detected. For the dose-adjusted trough concentration ratio (Ctrough/D) of rivaroxaban, the homozygous mutant type was significantly lower than wild type at ABCB1 rs4148738 locus (TT vs. CC, P = 0.033), and the mutant type was significantly lower than the wild type at ABCB1 rs4728709 locus (AA + GA vs. GG, P = 0.008). ABCB1 (rs1045642, rs1128503), CYP3A4 (rs2242480, rs4646437), CYP3A5 (rs776746), and ABCG2 (rs2231137, rs2231142) gene polymorphisms had no significant effect on the Ctrough/D of rivaroxaban. For the bleeding events, we found that there were no significant differences among genotypes of all gene loci.

Conclusion

This study found for the first time that ABCB1 rs4148738 and rs4728709 gene polymorphisms had a significant impact on the Ctrough/D of rivaroxaban in NVAF patients. CYP3A4/5, ABCB1, and ABCG2 gene polymorphisms were not associated with the bleeding risk of rivaroxaban.

Introduction

Compared with warfarin, direct oral anticoagulants (DOACs) have many advantages, including rapid onset of action, no food interaction, less drug interaction, predictable pharmacokinetics and pharmacodynamics, etc [1] . DOACs have gradually been widely used in clinical practice, especially the use rate of rivaroxaban, which rose from 0.13% to 13.87% from 2011 to 2014 [2]. Non-valvular atrial fibrillation (NVAF) is one of the most common arrhythmias, which can increase the risk of ischemic stroke by about five times [3]. Oral anticoagulation therapy is an effective means to prevent thromboembolism in patients with NVAF. Studies have shown that the safety and effectiveness of rivaroxaban in patients with NVAF are as good as warfarin [4]. Although rivaroxaban does not require routine testing, it has been found that there are large inter-individual differences in patients with NVAF [5, 6].

Rivaroxaban is eliminated by dual hepatic and renal channels, and approximately two-thirds of rivaroxaban is metabolized by hepatic cytochrome P450 (CYP450) to inactive metabolites, mainly by CYP3A4/5 (approximately 18%) and CYP2J2 (approximately 14%) [7, 8]. Rivaroxaban is not only a substrate for CYP3A4/5 and CYP2J2, but also a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) efflux transporters, which are abundant in epithelial cells of organs such as liver, intestine and kidney and may affect the PK process of the drug [9, 10]. CYP3A4/5, CYP2J2, P-gp and BCRP play important roles in the transport and metabolism of rivaroxaban. While the ATP-binding cassette subfamily B member 1(ABCB1) gene encodes P-gp, the ATP-binding cassette superfamily G member 2 (ABCG2) gene encodes BRCP [9, 11]. Therefore genetic polymorphisms in CYP3A4/5, CYP2J2, ABCB1 and ABCG2 may affect their functions and alter the pharmacokinetics of rivaroxaban, thus having an impact on the safety and efficacy of the drug.

Interindividual genetic variations in drug-metabolizing enzymes and transporters influence the pharmacokinetics and pharmacodynamics of various drugs [12]. Studies have shown that the inter-individual differences of rivaroxaban may be related to the gene polymorphisms of related metabolic enzymes and transporters [13]. At present, there are limited studies of gene polymorphisms about rivaroxaban, and the results are contradictory. Therefore, it is necessary to explore the influence of genetic factors on the pharmacokinetics of rivaroxaban further. Previous studies mostly analyzed the relationship between the plasma concentrations and gene polymorphisms [14,15,16] or investigated the impact of single gene polymorphism on trough concentration and bleeding events [17]. Therefore, the purpose of this study is to explore the effects of multiple gene polymorphisms (CYP3A4/5, ABCB1, and ABCG2) on the plasma concentrations of rivaroxaban and bleeding events, which may provide references for rational clinical use of rivaroxaban and further exploration of the influence of genes on the pharmacokinetics and clinical outcomes of rivaroxaban.

Methods

Study design and participants

This is a prospective multicenter study. It was carried out from September 2018 to September 2020. Inclusion criteria: more than 18 years old; diagnosed as NVAF; receiving rivaroxaban anticoagulant therapy. Exclusion criteria: combined with CYP3A4 or P-gp inducers or inhibitors (dronedarone, verapamil, quinidine, ticagrelor, clarithromycin, erythromycin, HIV protease inhibitors, azole antifungal drugs, rifampicin, carbamazepine, phenobarbital, valproic acid, and phenytoin) [5], severe liver impairment (Child–Pugh B/C and liver cirrhosis) or renal dysfunction (estimated glomerular filtration rate [eGFR] < 30 ml/(min*1.73 m2; comorbidities with significant risk for bleeding such as peptic ulcer and thrombocytopenia, or clinically active bleeding; unable to fulfill the follow-up visits. Informed consent was obtained from all individual participants included in the study. The studies involving human participants were reviewed and approved by Fujian Medical University Union Hospital Ethics Committee.

The patients took rivaroxaban (10/15/20 mg once daily) for at least one week. And then, peripheral venous blood was collected within 30 min before administration in the morning to detect the steady-state trough plasma concentrations and gene polymorphisms. We visited the patients at months 1, 3, 6, and 12 and recorded the medications, bleeding events, etc.

Determination of plasma concentrations

We used the validated high-performance liquid chromatography/tandem mass (HPLC–MS/MS) method to detect the plasma concentrations of rivaroxaban [18]. This method used rivaroxaban-d4 as the internal standard, and the blood samples were processed by the protein precipitation method. The running time was 6 min. The linear range of the calibration curve was 2–500 ng/mL, and the calibration curve showed good linearity with R = 0.9998. The method was fast, accurate, and sensitive.

Determination of gene polymorphisms

This study investigated the gene polymorphisms at the following gene loci: ABCB1 (rs1045642, rs1128503, rs4148738, and rs4728709), CYP3A4 (rs2242480 and rs4646437), CYP3A5 (rs776746), and ABCG2 (rs2231137 and rs2231142), a total of 9 gene loci. Gene polymorphisms were detected by Massarray SNP typing technology, completed by BGI Tech Solutions (Beijing Liuhe) co., Limited.

Statistical analysis

The chi-square test evaluated whether the allele frequencies distribution of genes conformed to the Hardy–Weinberg equilibrium. Kruskal–Wallis test was used to compare continuous variables. Categorical variables were compared using the Chi-square or Fisher's Exact tests. Results with P < 0.05 were considered statistically significant. Statistical analysis was performed using SPSS 26.0.

One study reported that rivaroxaban clearance decreased with increasing renal impairment, leading to increased plasma exposure and increased pharmacodynamic effects [19]. Meanwhile, in the PPK study of rivaroxaban in NVAF patients, creatinine clearance, age and body weight were found to have a significant effect on the PK of rivaroxaban [6]. Amiodarone is a commonly used combination drug for the treatment of patients with atrial fibrillation and is a moderate CYP3A4 inhibitor and P-gp inhibitor [20]. Amiodarone has a minor effect on rivaroxaban blood levels [5]. However, A study also found an increased risk of bleeding in patients taking rivaroxaban in combination with amiodarone than without amiodarone [21]. The tools commonly used in clinical practice to assess the risk of bleeding and thrombosis in patients with non-valvular atrial fibrillation are the HAS-BLED and CHA2DS2-VASc score, respectively. To avoid the influence of patients' own bleeding and thrombotic risks on the results of this study, they were included as confounding factors. In summary, to exclude the influence of the above confounding factors on the plasma concentrations of rivaroxaban, we analyzed whether there were differences in the ratio of amiodarone, age, weight, creatinine clearance (CrCl), CHA2DS2-VASc scores, and HAS-BLED scores among genotypes.

Results

We enrolled a total of 95 patients, including 56 males and 39 females, with an average age of 66 years. The patients mainly received rivaroxaban 15 mg once daily. The patient's baseline characteristics are shown in Table 1. The allele frequencies distribution of all genes conformed to the Hardy–Weinberg equilibrium (Table 2).

Table 1 Baseline characteristics of the patients
Full size table
Table 2 Distribution of genotypes and allele frequencies
Full size table

Impact of gene polymorphisms on plasma concentrations

A total of 9 single nucleotide polymorphisms (SNPs) were investigated in this study, including ABCB1 (4 SNPs), CYP3A4/5 (3 SNPs), and ABCG2 (2 SNPs). The results showed that ABCB1 SNP rs4148738 (P = 0.039) and SNP rs4728709 (P = 0.029) had a significant effect on the Ctrough/D of rivaroxaban (Table 3). For ABCB1 rs4148738, the results of multiple comparisons showed that the homozygous mutant type was associated with a significantly lower Ctrough/D than wild type (TT vs. CC, P = 0.033), while the Ctrough/D between the heterozygous mutant type and homozygous mutant type or wild type did not show a significant difference (CT vs. TT, P = 0.611; CT vs. CC, P = 0.242) (Table 4). For ABCB1 rs4728709, the results of multiple comparisons showed that the homozygous mutant type had a significantly lower Ctrough/D than wild type (GA vs. GG, P = 0.032), while the Ctrough/D between the homozygous mutant type and wild type or heterozygous mutant type was similar (AA vs. GG, P = 1.00; AA vs. GA, P = 1.00) (Table 4). We tried to compare the mutant type (AA + GA) with wild type (GG), and the results showed that the mutant type had a significantly lower Ctrough/D of rivaroxaban than wild type (P = 0.008). The study did not find that ABCB1 (rs1045642 and rs1128503), CYP3A4 (rs2242480 and rs4646437), CYP3A5 (rs776746), and ABCG2 (rs2231137 and rs2231142) gene polymorphisms had a significant effect on the Ctrough/D of rivaroxaban.

Table 3 Comparison of the rivaroxaban Ctrough/D among genotypes
Full size table
Table 4 Pair comparison of Cthrough/D between ABCB1 rs4148738(C > T) and ABCB1 rs4728709 (G > A) genotypes
Full size table

Impact of gene polymorphisms on bleeding events

A total of 16 bleeding events were found in this study, including 9 gingival bleedings, 3 conjunctiva hemorrhages, 3 hematurias, and 1 epistaxis. The study found no significant differences in the incidences of bleeding events among genotypes of all SNPs (Table 5).

Table 5 Comparison of bleeding events among genotypes
Full size table

To exclude the influence of other confounding factors on the plasma concentrations of rivaroxaban, this study also analyzed and compared the ratio of amiodarone, age, weight, CrCl, CHA2DS2-VASc scores, and HAS-BLED scores among genotypes for all gene loci. The results showed that the above confounding factors were almost similar among genotypes, except for the significant difference in the ratio of amiodarone for ABCG2 rs2231137 (Table 6).

Table 6 Comparison of confounding factors among genotypes
Full size table

Discussion

This is the first study to comprehensively evaluate the effects of multiple gene polymorphisms on the steady-state trough concentration of rivaroxaban and bleeding events in patients with NVAF. This study found that ABCB1 rs4148738 and rs4728709 gene polymorphisms were associated with the Ctrough/D of rivaroxaban for the first time, which may provide a reference for the exploration of the influence of genetic factors on the pharmacokinetics of rivaroxaban.

At present, there are limited studies on the relationship between CYP450 gene polymorphisms and rivaroxaban. Sychev et al. [22] reported a significant correlation between CYP3A activity and rivaroxaban peak and trough levels in patients with deep vein thrombosis. In contrast, no significant correlation between CYP3A activity and treatment parameters was found. Nakagawa et al. [14] found the Ctrough/D of rivaroxaban did not differ significantly among CYP3A5*3 rs776746 and CYP2J2*7 rs890293 genotypes. Another study reported the peak steady-state rivaroxaban concentration between the heterozygous mutant type and wild-type for CYP3A4 rs35599367 and CYP3A5 rs776746 did not show a statistically significant difference in patients undergoing total hip and knee replacement surgery [8]. Our study also did not find that CYP3A4 (rs2242480, rs4646437) and CYP3A5 (rs776746) gene polymorphisms had a significant effect on the Ctrough/D of rivaroxaban. As far as we know, this is the first study to report the correlation between CYP450 gene polymorphisms and bleeding events of rivaroxaban, but our study found no significant correlation. Although no significant CYP450 gene locus for rivaroxaban has been found so far, CYP450 is an important metabolic enzyme of rivaroxaban, and the related studies are limited at present. Its gene polymorphism needs to be further studied.

The results of previously published studies on the relationship between gene polymorphisms and rivaroxaban are inconsistent. A case report showed that the ABCB1 gene mutation (rs1045642 and rs2032582) might lead to the prolonged half-life of rivaroxaban, which was related to the bleeding in an elderly patient with atrial fibrillation [23]. But some vivo and vitro studies (cell experiments, healthy Caucasians, patients undergoing total hip and knee replacement surgery, and NVAF patients) reported no significant correlation between the ABCB1 (rs1128503, rs1045642, rs2032582, and rs4148738) gene polymorphisms and inter-individual pharmacokinetic variability of rivaroxaban was found [8, 15, 16, 24, 25]. Our study investigated four ABCB1 SNPs, and the results showed that ABCB1 SNP rs4148738 and SNP rs4728709 had a significant effect on the Ctrough/D of rivaroxaban. However, ABCB1 SNP rs1045642 and SNP rs1128503 had no significant effect on the Ctrough/D of rivaroxaban. As far as we know, only two studies have explored the relationship between gene polymorphisms and the bleeding risk of rivaroxaban. Wang et al. reported no significant correlation between ABCB1 gene variation loci rs1045642, rs1128503, rs4148738 and bleeding events in patients with atrial fibrillation [17]. In a real-world study in 2021, ABCB1 gene polymorphisms (rs1045642, rs1128503, rs2032582) were not associated with the bleeding risk rivaroxaban [26]. Our analysis also did not find that the ABCB1 gene polymorphisms significantly impacted the bleeding events of rivaroxaban.

This study showed that the ABCB1 rs4148738 homozygous mutant type (TT) was associated with a significantly lower rivaroxaban Ctrough/D than wild type (CC), which means that patients with the TT genotype may have a lower bleeding risk than the CC genotype. Dimatteo et al. found that the ABCB1 rs4148738 mutant type showed 5% lower trough concentrations of dabigatran compared with the wild type [24]. Lähteenmäki et al. also reported that compared with rs4148738 CC genotype, CT + TT genotype was associated with a reduced bleeding risk of apixaban [26]. The ABCB1 rs4148738 homozygous mutant type reduced the Ctrough/D of rivaroxaban, suggesting that thrombotic events may occur when other factors can reduce the plasma concentration rivaroxaban are combined, such as the combination with CYP450/P-gp inducers (rifampicin, phenytoin sodium, doxorubicin, etc.) [5].

Our study showed that the ABCB1 rs4728709 heterozygous mutant type (GA) had a significantly lower Ctrough/D of rivaroxaban than wild type (GG). A study reported that the ABCB1 rs4728709 mutation could significantly increase the clearance rate of dexamethasone [27]. Dexamethasone is also a substrate of P-gp. An increase in clearance rate means a decrease in plasma concentration. The result is consistent with ours. The above results suggest that it may be necessary to pay attention to whether patients with mutations at this gene locus will have insufficient anticoagulation, especially when combined with CYP3A4 or P-gp inducers.

Nakagawa et al. reported that the Ctrough/D of rivaroxaban in patients with AF did not differ significantly among ABCG2 c.421C > A (rs2231142) genotypes [14]. But they did not examine the effect of ABCG2 gene polymorphisms on the bleeding events of rivaroxaban. Tandia et al. reported that ABCG2 rs2231137 gene polymorphism was associated with plasma concentrations of sorafenib [28]. Studies have also found that ABCG2 rs2231142 genotypes GT + TT were associated with increased exposure to sunitinib in people with neoplasms and increased plasma concentrations of rosuvastatin compared to genotype GG [29, 30]. This is the first study to investigate the impact of ABCG2 gene polymorphisms on rivaroxaban's pharmacokinetics and bleeding events simultaneously, and no significant effects were found. This result may provide references for future exploration of the influence of ABCG2 gene polymorphisms on rivaroxaban's pharmacokinetics and clinical outcomes.

Overall, there are fewer studies on the relevance of gene polymorphisms on the pharmacokinetics of rivaroxaban to the clinical outcome of rivaroxaban. Most studies have focused on the ABCB1 gene, and the findings are somewhat contradictory. A total of nine genetic loci related to rivaroxaban metabolizing enzymes and transporters were examined in this study. We hope that the results of this study will be useful for the subsequent exploration of the influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban. On one hand, this study provides some reference for further exploring genetic factors in the construction of a model of bleeding with rivaroxaban in patients with NVAF, which should be applied to predict the risk of bleeding with rivaroxaban and reduce the occurrence of adverse effects in clinical practice. On the other hand, it provides a certain reference in constructing a PPK/PD model of rivaroxaban in patients with NVAF, and helps to individualize and rationalize the clinical use of drugs.

This study has several limitations. Firstly, when analyzing bleeding events, we found that three gene loci did not meet the requirements of the R*C chi-square test, including ABCB1 rs4148738, rs4728709, and CYP3A4 rs4646437. So we combined heterozygous mutant type with homozygous mutant type and compared them with wild type. Therefore, we could only compare whether there were differences in bleeding events between the mutant and wild types at these three gene loci, but not multiple comparisons among three genotypes. Secondly, to eliminate the influence of confounding factors, this study further compared the ratio of amiodarone, age, weight, CrCl, CHA2DS2-VASc scores, and HAS-BLED scores among genotypes. However, it was found that there were significant differences in the ratio of amiodarone among genotypes at ABCG2 rs2231137. Amiodarone is an inhibitor of CYP3A4 and P-gp. Studies have reported that amiodarone has a minor effect on the plasma concentrations of rivaroxaban [5]. So it may affect the final interpretation of the results of ABCG2 rs2231137 in this study. Finally, due to the small sample size of this study, a later study with a larger clinical sample size is needed to further validate the results.

In general, there are limited studies on the influence of gene polymorphisms on the pharmacokinetics of rivaroxaban, and there are fewer studies on the correlation between gene polymorphisms and the clinical outcomes of rivaroxaban. Most studies focus on the ABCB1 gene, and the results are also contradictory. This study investigated 9 gene loci related to rivaroxaban metabolic enzymes and transporters. It is hoped that the results will be helpful to the subsequent exploration of the influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban.

Conclusions

This study suggests that the ABCB1 rs4148738 and rs4728709 gene polymorphisms significantly impacted the trough concentration of rivaroxaban. CYP3A4/5, ABCB1, and ABCG2 gene polymorphisms were not associated with rivaroxaban bleeding events, and the relationship between genetic polymorphisms and bleeding events needs to be further investigated verified by the large sample size.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost. 2010;8(4):621–6.

    Article  Google Scholar 

  2. Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237–44.

    Article  PubMed  Google Scholar 

  3. Blin P, Fauchier L, Dureau-Pournin C, et al. Effectiveness and safety of rivaroxaban 15 or 20 mg versus vitamin K antagonists in nonvalvular atrial fibrillation. Stroke. 2019;50(9):2469–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  CAS  PubMed  Google Scholar 

  5. Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76.

    Article  PubMed  Google Scholar 

  6. Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54(8):917–27.

    Article  CAS  PubMed  Google Scholar 

  7. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27–32.

    Article  CAS  PubMed  Google Scholar 

  8. Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 gene polymorphisms on rivaroxaban pharmacokinetics in patients undergoing total hip and knee replacement surgery. High Blood Press Cardiovasc Prev. 2019;26(5):413–20.

    Article  CAS  PubMed  Google Scholar 

  9. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338(1):372–80.

    Article  CAS  PubMed  Google Scholar 

  10. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–37.

    Article  CAS  PubMed  Google Scholar 

  11. Gong IY, Mansell SE, Kim RB. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013;112(3):164–70.

    Article  CAS  PubMed  Google Scholar 

  12. Ahmed S, Zhou Z, Zhou J, et al. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinform. 2016;14(5):298–313.

    Article  Google Scholar 

  13. Kanuri SH, Kreutz RP. Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019;9(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nakagawa J, Kinjo T, Iizuka M, et al. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021;128(2):297–304.

    Article  CAS  PubMed  Google Scholar 

  15. Zdovc J, Petre M, Pišlar M, et al. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019;75(6):817–24.

    Article  CAS  PubMed  Google Scholar 

  16. Chen M, Chen H, Ling WW, et al. Population pharmacokinetics of rivaroxaban in patients with nonvalvular atrial fibrillation. J Clin Cardiol. 2020;36(8):724–30.

    Google Scholar 

  17. Wang Y, Chen M, Chen H, et al. Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol. 2021;12: 639854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wu TT, Xia XT, Fu JL, et al. Simultaneous concentration determination of dabigatran and rivaroxaban in human plasma by LC-MS/MS. Chin J Clin Pharmacol. 2019;35(10):120–3.

    Google Scholar 

  19. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mar PL, Horbal P, Chung MK, et al. drug interactions affecting antiarrhythmic drug use. Circ Arrhythm Electrophysiol. 2022;15(5): e007955.

    Article  CAS  PubMed  Google Scholar 

  21. Hanigan S, Das J, Pogue K, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636–43.

    Article  CAS  PubMed  Google Scholar 

  22. Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A activity and rivaroxaban serum concentrations in Russian patients with deep vein thrombosis. Genet Test Mol Biomarkers. 2018;22(1):51–4.

    Article  CAS  PubMed  Google Scholar 

  23. Ing Lorenzini K, Daali Y, Fontana P, et al. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol. 2016;19(7):494.

    Google Scholar 

  24. Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5.

    Article  CAS  PubMed  Google Scholar 

  25. Sennesael AL, Panin N, Vancraeynest C, et al. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. Sci Rep. 2018;8(1):10514.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lähteenmäki J, Vuorinen AL, Pajula J, et al. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. Clin Pharmacol Ther. 2021;110(3):768–76.

    Article  PubMed  Google Scholar 

  27. Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood. 2012;120(20):4197–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemother Pharmacol. 2017;79(4):759–66.

    Article  CAS  PubMed  Google Scholar 

  29. DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015;33(1):257–68.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Author notes

  1. Tingting Wu and Shuyi Wu contributed to the work equally.

Authors and Affiliations

  1. Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, #18 Daoshan Road, Fuzhou, 350001, China

    Tingting Wu, Shuyi Wu, Wenjun Chen & Jinhua Zhang

  2. Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, China

    Li Li

  3. Department of Pharmacy, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Jing Xiang & Na Wang

Authors
  1. Tingting Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuyi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Na Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenjun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jinhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TW and JZ designed the study. TW, SW, LL, JX, NW, and WC collected and analyzed the data; TW and SW interpreted the data and drafted the manuscript; JZ critically revised the manuscript and supervised the work. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Jinhua Zhang.

Ethics declarations

Ethics approval and consent to participate

The studies involving human participants were reviewed and approved by Fujian Medical University Union Hospital Ethics Committee (Number: 2018YF005-02, date: 2018-3-14). Informed consent was obtained from all individual participants included in the study.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, T., Wu, S., Li, L. et al. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. Hum Genomics 17, 59 (2023). https://doi.org/10.1186/s40246-023-00506-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40246-023-00506-3

Keywords

Human Genomics

ISSN: 1479-7364